pharmaphorum37m
Novo Nordisk asks FDA not to allow GLP-1 compounding
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
Is Novo Nordisk an Undervalued Stock to Buy Now?
Novo Nordisk (NYSE: NVO) has sparked investor interest primarily because of its weight loss treatments. Where to invest ...
University of Arkansas5h
Juleen Zierath to Explore Exercise's Impact on Skeletal Muscle and Metabolic Health
AIMRC & WECARE will host Juleen Zierath of the Karolinska Institute, Stockholm, at 12:55 p.m. Wednesday, Jan. 15, at the Jones Family Student-Athlete Success Center, room 104.
BioSpace6h
Evidence Mounts for Benefit of GLP-1s Against Heart Disease
Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...
Price must be right to put obesity pill on the PBS
Whether to fully subsidise the new generation weight loss drugs such as Mounjaro and Ozempic for obese Australians without ...
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
Global pharma giants push for weight-loss drugs to be added to PBS
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...
What's Going on With Novo Nordisk Stock?
Novo Nordisk (NYSE: NVO) has found phenomenal success in treating patients with obesity and diabetes. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...